OptiNose (OPTN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

OPTN Stock Forecast

OptiNose stock forecast is as follows: an average price target of $1.00 (represents a -83.33% downside from OPTN’s last price of $6.00) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

OPTN Price Target

The average price target for OptiNose (OPTN) is $1.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $1.00 to $1.00. This represents a potential -83.33% downside from OPTN's last price of $6.00.

OPTN Analyst Ratings

Buy

According to 6 Wall Street analysts, OptiNose's rating consensus is 'Buy'. The analyst rating breakdown for OPTN stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

OptiNose Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 13, 2024	David Amsellem	Piper Sandler	$1.00	$0.89	12.36%	-83.33%
May 15, 2024	Thomas Flaten	Loop Capital Markets	$3.00	$1.12	167.86%	-50.00%
Nov 14, 2022		BMO Capital	$5.00	$2.01	148.76%	-16.67%
Jun 13, 2022	David Amsellem	Piper Sandler	$4.00	$2.62	52.56%	-33.33%

The latest OptiNose stock forecast, released on Nov 13, 2024 by David Amsellem from Piper Sandler, set a price target of $1.00, which represents a 12.36% increase from the stock price at the time of the forecast ($0.89), and a -83.33% decrease from OPTN last price ($6.00).

OptiNose Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	2
Avg Price Target	-	$1.00	$2.00
Last Closing Price	$6.00	$6.00	$6.00
Upside/Downside	-100.00%	-83.33%	-66.67%

In the current month, the average price target of OptiNose stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to OptiNose's last price of $6.00. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jan 03, 2025	H.C. Wainwright	Buy	Buy	Hold
Nov 13, 2024	Piper Sandler	Overweight	Overweight	Hold
May 15, 2024	Lake Street	Buy	Buy	Hold
Aug 21, 2023	Cowen & Co.		Outperform	Initialise
Aug 21, 2023	Lake Street		Buy	Initialise
Aug 21, 2023	Noble Capital Markets		Outperform	Initialise
Nov 14, 2022	BMO Capital	Outperform	Outperform	Hold
Jun 13, 2022	Piper Sandler	Overweight	Overweight	Hold

OptiNose's last stock rating was published by H.C. Wainwright on Jan 03, 2025. The company gave OPTN a "Buy" rating, the same as its previous rate.

OptiNose Financial Forecast

OptiNose Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18
Revenue	-	-	-	-	-	-	-	-	$19.86M	$19.82M	$19.45M	$11.85M	$20.86M	$20.08M	$20.58M	$14.76M	$22.51M	$21.83M	$18.36M	$11.96M	$16.35M	$15.44M	$10.27M	$7.06M	$11.08M	$12.40M	$6.68M	$4.48M	$865.00K
Avg Forecast	$31.80M	$27.60M	$24.20M	$17.70M	$21.02M	$22.95M	$20.58M	$14.90M	$19.26M	$18.68M	$17.36M	$9.85M	$20.71M	$23.35M	$20.55M	$16.71M	$21.75M	$23.50M	$18.08M	$11.17M	$17.92M	$14.58M	$9.79M	$7.72M	$11.64M	$8.58M	$6.62M	$3.80M	$779.57K
High Forecast	$31.80M	$27.60M	$24.20M	$17.70M	$23.83M	$22.98M	$20.58M	$14.90M	$19.26M	$18.68M	$17.36M	$9.85M	$22.10M	$23.35M	$20.55M	$16.71M	$21.75M	$23.50M	$18.08M	$11.17M	$17.92M	$14.58M	$9.79M	$7.72M	$11.64M	$8.58M	$6.62M	$3.80M	$935.48K
Low Forecast	$31.80M	$27.60M	$24.20M	$17.70M	$19.56M	$22.93M	$20.58M	$14.90M	$19.26M	$18.68M	$17.36M	$9.85M	$19.88M	$23.35M	$20.55M	$16.71M	$21.75M	$23.50M	$18.08M	$11.17M	$17.92M	$14.58M	$9.79M	$7.72M	$11.64M	$8.58M	$6.62M	$3.80M	$623.65K
# Analysts	1	1	1	1	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	13	7	7	9	8	6	10	6	14
Surprise %	-	-	-	-	-	-	-	-	1.03%	1.06%	1.12%	1.20%	1.01%	0.86%	1.00%	0.88%	1.03%	0.93%	1.02%	1.07%	0.91%	1.06%	1.05%	0.91%	0.95%	1.44%	1.01%	1.18%	1.11%

OptiNose's average Quarter revenue forecast for Mar 24 based on 1 analysts is $14.90M, with a low forecast of $14.90M, and a high forecast of $14.90M. OPTN's average Quarter revenue forecast represents a -24.99% decrease compared to the company's last Quarter revenue of $19.86M (Dec 23).

OptiNose EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18
# Analysts	1	1	1	1	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	13	7	7	9	8	6	10	6	14
EBITDA	-	-	-	-	-	-	-	-	$-4.95M	$-1.69M	$-4.17M	$-14.37M	$-8.36M	$-10.61M	$-15.17M	$-21.14M	$-11.44M	$-12.57M	$-19.33M	$-22.01M	$-19.94M	$-17.39M	$-22.30M	$-25.68M	$-22.29M	$-26.15M	$-24.66M	$-26.22M	$-28.22M
Avg Forecast	$-24.50M	$-21.26M	$-18.64M	$-13.64M	$-16.20M	$-17.68M	$-15.86M	$-11.48M	$-14.84M	$-14.39M	$-13.38M	$-7.59M	$-15.96M	$-18.39M	$-16.18M	$-18.01M	$-17.13M	$-18.51M	$-14.24M	$-23.67M	$-14.11M	$-11.48M	$-7.71M	$-26.47M	$-9.17M	$-6.76M	$-5.21M	$-26.59M	$-25.13M
High Forecast	$-24.50M	$-21.26M	$-18.64M	$-13.64M	$-15.07M	$-17.66M	$-15.86M	$-11.48M	$-14.84M	$-14.39M	$-13.38M	$-7.59M	$-15.32M	$-18.39M	$-16.18M	$-14.41M	$-17.13M	$-18.51M	$-14.24M	$-18.94M	$-14.11M	$-11.48M	$-7.71M	$-21.18M	$-9.17M	$-6.76M	$-5.21M	$-21.27M	$-20.10M
Low Forecast	$-24.50M	$-21.26M	$-18.64M	$-13.64M	$-18.36M	$-17.70M	$-15.86M	$-11.48M	$-14.84M	$-14.39M	$-13.38M	$-7.59M	$-17.02M	$-18.39M	$-16.18M	$-21.61M	$-17.13M	$-18.51M	$-14.24M	$-28.41M	$-14.11M	$-11.48M	$-7.71M	$-31.77M	$-9.17M	$-6.76M	$-5.21M	$-31.90M	$-30.16M
Surprise %	-	-	-	-	-	-	-	-	0.33%	0.12%	0.31%	1.89%	0.52%	0.58%	0.94%	1.17%	0.67%	0.68%	1.36%	0.93%	1.41%	1.51%	2.89%	0.97%	2.43%	3.87%	4.73%	0.99%	1.12%

undefined analysts predict OPTN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than OptiNose's previous annual EBITDA (undefined) of $NaN.

OptiNose Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18
# Analysts	1	1	1	1	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	13	7	7	9	8	6	10	6	14
Net Income	-	-	-	-	-	-	-	-	$-10.16M	$-9.29M	$2.63M	$-18.65M	$-17.33M	$-14.95M	$-19.40M	$-25.33M	$-19.64M	$-17.12M	$-23.50M	$-26.05M	$-23.86M	$-21.21M	$-25.85M	$-28.86M	$-25.00M	$-28.81M	$-27.38M	$-28.87M	$-30.57M
Avg Forecast	$52.31M	$-26.16M	$-78.47M	$-130.78M	$-132.52M	$-137.32M	$-202.31M	$-277.90M	$-246.90M	$-246.78M	$-283.86M	$-366.18M	$-30.47M	$-28.05M	$-36.54M	$-21.58M	$-39.18M	$-53.95M	$-62.79M	$-28.02M	$-69.57M	$-78.86M	$-84.39M	$-29.74M	$-93.43M	$-106.39M	$-110.91M	$-29.28M	$-27.22M
High Forecast	$52.31M	$-26.16M	$-78.47M	$-130.78M	$-118.68M	$-137.32M	$-202.31M	$-277.90M	$-222.21M	$-246.78M	$-283.86M	$-366.18M	$-28.89M	$-28.05M	$-36.54M	$-17.26M	$-39.18M	$-53.95M	$-62.79M	$-22.42M	$-69.57M	$-78.86M	$-84.39M	$-23.80M	$-93.43M	$-106.39M	$-110.91M	$-23.42M	$-21.78M
Low Forecast	$52.31M	$-26.16M	$-78.47M	$-130.78M	$-148.35M	$-137.32M	$-202.31M	$-277.90M	$-246.90M	$-246.78M	$-283.86M	$-366.18M	$-33.12M	$-28.05M	$-36.54M	$-25.90M	$-39.18M	$-53.95M	$-62.79M	$-33.62M	$-69.57M	$-78.86M	$-84.39M	$-35.69M	$-93.43M	$-106.39M	$-110.91M	$-35.14M	$-32.67M
Surprise %	-	-	-	-	-	-	-	-	0.04%	0.04%	-0.01%	0.05%	0.57%	0.53%	0.53%	1.17%	0.50%	0.32%	0.37%	0.93%	0.34%	0.27%	0.31%	0.97%	0.27%	0.27%	0.25%	0.99%	1.12%

OptiNose's average Quarter net income forecast for Sep 23 is $-246.78M, with a range of $-246.78M to $-246.78M. OPTN's average Quarter net income forecast represents a -9497.71% decrease compared to the company's last Quarter net income of $2.63M (Jun 23).

OptiNose SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18
# Analysts	1	1	1	1	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	13	7	7	9	8	6	10	6	14
SG&A	-	-	-	-	-	-	-	-	$18.96M	$18.01M	$20.10M	$22.72M	$23.31M	$25.49M	$29.51M	$29.34M	$26.34M	$25.80M	$27.31M	$27.18M	$28.11M	$24.57M	$25.70M	$27.06M	$26.55M	$25.27M	$26.00M	$26.34M	$27.82M
Avg Forecast	$57.99M	$50.33M	$44.13M	$32.28M	$38.34M	$41.86M	$37.53M	$27.17M	$35.13M	$34.07M	$31.66M	$17.96M	$37.77M	$42.56M	$37.45M	$30.45M	$39.64M	$42.83M	$32.95M	$20.35M	$32.66M	$26.57M	$17.85M	$14.07M	$21.21M	$15.64M	$12.06M	$6.93M	$1.42M
High Forecast	$57.99M	$50.33M	$44.13M	$32.28M	$43.45M	$41.90M	$37.53M	$27.17M	$35.13M	$34.07M	$31.66M	$17.96M	$40.30M	$42.56M	$37.45M	$30.45M	$39.64M	$42.83M	$32.95M	$20.35M	$32.66M	$26.57M	$17.85M	$14.07M	$21.21M	$15.64M	$12.06M	$6.93M	$1.70M
Low Forecast	$57.99M	$50.33M	$44.13M	$32.28M	$35.66M	$41.81M	$37.53M	$27.17M	$35.13M	$34.07M	$31.66M	$17.96M	$36.26M	$42.56M	$37.45M	$30.45M	$39.64M	$42.83M	$32.95M	$20.35M	$32.66M	$26.57M	$17.85M	$14.07M	$21.21M	$15.64M	$12.06M	$6.93M	$1.14M
Surprise %	-	-	-	-	-	-	-	-	0.54%	0.53%	0.64%	1.27%	0.62%	0.60%	0.79%	0.96%	0.66%	0.60%	0.83%	1.34%	0.86%	0.92%	1.44%	1.92%	1.25%	1.62%	2.16%	3.80%	19.58%

OptiNose's average Quarter SG&A projection for Mar 24 is $27.17M, based on 1 Wall Street analysts, with a range of $27.17M to $27.17M. The forecast indicates a 43.30% rise compared to OPTN last annual SG&A of $18.96M (Dec 23).

OptiNose EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18
# Analysts	1	1	1	1	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	13	7	7	9	8	6	10	6	14
EPS	-	-	-	-	-	-	-	-	$-0.00	$-0.08	-	$-0.17	$-0.18	$-0.18	$-0.23	$-0.31	$-0.29	$-0.32	$-0.44	$-0.49	$-0.46	$-0.43	$-0.56	$-0.63	$-0.58	$-0.69	$-0.66	$-0.70	$-0.81
Avg Forecast	$0.30	$-0.15	$-0.45	$-0.75	$-0.76	$-0.79	$-1.16	$-1.59	$-1.42	$-1.42	$-1.63	$-2.10	$-0.17	$-0.19	$-0.24	$-0.27	$-0.26	$-0.36	$-0.42	$-0.53	$-0.46	$-0.52	$-0.56	$-0.66	$-0.62	$-0.71	$-0.74	$-0.71	$-0.65
High Forecast	$0.30	$-0.15	$-0.45	$-0.75	$-0.68	$-0.79	$-1.16	$-1.59	$-1.27	$-1.42	$-1.63	$-2.10	$-0.17	$-0.19	$-0.24	$-0.27	$-0.26	$-0.36	$-0.42	$-0.53	$-0.46	$-0.52	$-0.56	$-0.66	$-0.62	$-0.71	$-0.74	$-0.71	$-0.52
Low Forecast	$0.30	$-0.15	$-0.45	$-0.75	$-0.85	$-0.79	$-1.16	$-1.59	$-1.42	$-1.42	$-1.63	$-2.10	$-0.19	$-0.19	$-0.24	$-0.27	$-0.26	$-0.36	$-0.42	$-0.53	$-0.46	$-0.52	$-0.56	$-0.66	$-0.62	$-0.71	$-0.74	$-0.71	$-0.78
Surprise %	-	-	-	-	-	-	-	-	0.00%	0.06%	-	0.08%	1.03%	0.97%	0.95%	1.15%	1.12%	0.89%	1.06%	0.92%	1.00%	0.82%	1.00%	0.96%	0.94%	0.98%	0.90%	0.98%	1.25%

According to undefined Wall Street analysts, OptiNose's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to OPTN previous annual EPS of $NaN (undefined).

OptiNose Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PROC	Procaps Group	$1.52	$10.00	557.89%
KMDA	Kamada	$6.74	$20.00	196.74%
IRWD	Ironwood Pharmaceuticals	$3.72	$8.50	128.49%	Buy
DVAX	Dynavax	$12.98	$24.50	88.75%	Buy
AMPH	Amphastar Pharmaceuticals	$36.42	$66.00	81.22%	Buy
EOLS	Evolus	$14.56	$24.00	64.84%	Buy
COLL	Collegium Pharmaceutical	$32.42	$42.33	30.57%	Buy
ANIP	ANI Pharmaceuticals	$59.35	$71.50	20.47%	Buy
ALKS	Alkermes	$31.56	$37.50	18.82%	Hold
PBH	Prestige Consumer Healthcare	$78.79	$86.00	9.15%	Buy
LFCR	Lifecore Biomedical	$6.05	$6.50	7.44%	Buy
NBIX	Neurocrine Biosciences	$150.68	$155.00	2.87%	Buy
PAHC	Phibro Animal Health	$21.90	$18.67	-14.75%	Buy
ITCI	Intra-Cellular Therapies	$127.02	$105.67	-16.81%	Buy
OPTN	OptiNose	$6.00	$1.00	-83.33%	Buy

OPTN Forecast FAQ

Is OptiNose a good buy?

Yes, according to 6 Wall Street analysts, OptiNose (OPTN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of OPTN's total ratings.

What is OPTN's price target?

OptiNose (OPTN) average price target is $1 with a range of $1 to $1, implying a -83.33% from its last price of $6. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will OptiNose stock go up soon?

According to Wall Street analysts' prediction for OPTN stock, the company can go down by -83.33% (from the last price of $6 to the average price target of $1), down by -83.33% based on the highest stock price target, and down by -83.33% based on the lowest stock price target.

Can OptiNose stock reach $9?

OPTN's average twelve months analyst stock price target of $1 does not support the claim that OptiNose can reach $9 in the near future.

What are OptiNose's analysts' financial forecasts?

OptiNose's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $79.46M (high $82.29M, low $77.97M), average EBITDA is $-61.216M (high $-60.067M, low $-63.397M), average net income is $-750M (high $-736M, low $-766M), average SG&A $144.9M (high $150.06M, low $142.18M), and average EPS is $-4.301 (high $-4.222, low $-4.392). OPTN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $101.3M (high $101.3M, low $101.3M), average EBITDA is $-78.045M (high $-78.045M, low $-78.045M), average net income is $-183M (high $-183M, low $-183M), average SG&A $184.73M (high $184.73M, low $184.73M), and average EPS is $-1.05 (high $-1.05, low $-1.05).

Did the OPTN's actual financial results beat the analysts' financial forecasts?

Based on OptiNose's last annual report (Dec 2023), the company's revenue was $70.99M, beating the average analysts forecast of $65.15M by 8.95%. Apple's EBITDA was $-22.748M, missing the average prediction of $-50.197M by -54.68%. The company's net income was $-35.483M, missing the average estimation of $-1.144B by -96.90%. Apple's SG&A was $79.8M, missing the average forecast of $118.82M by -32.84%. Lastly, the company's EPS was $-0.0003, missing the average prediction of $-6.559 by -100.00%. In terms of the last quarterly report (Dec 2023), OptiNose's revenue was $19.86M, beating the average analysts' forecast of $19.26M by 3.12%. The company's EBITDA was $-4.948M, missing the average prediction of $-14.841M by -66.66%. OptiNose's net income was $-10.161M, missing the average estimation of $-247M by -95.88%. The company's SG&A was $18.96M, missing the average forecast of $35.13M by -46.03%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-1.416 by -99.99%